Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Pharmacokinetics in Obese Patients: Drug Absorption and Distribution01:25

Pharmacokinetics in Obese Patients: Drug Absorption and Distribution

Obesity significantly alters the pharmacokinetic processes of drug absorption and distribution, presenting unique challenges in medical treatment. The increased fat tissue and decreased lean muscle in obese individuals can significantly affect how drugs are absorbed into the body and distributed across different tissues. This alteration can lead to variances in the effectiveness and safety of medications, necessitating adjustments in dosing or drug selection for obese patients.One notable...
Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion01:20

Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion

Drug metabolism, a critical process in the liver, involves two primary phases: Phase I reactions and Phase II conjugation. Obesity introduces significant alterations in this metabolic process, primarily due to fatty infiltration of the liver, leading to conditions such as nonalcoholic fatty liver disease (NAFLD). This condition can modify the activities of both Phase I and II enzymes, impacting how drugs are metabolized in obese patients.Phase I metabolism sees variable effects across...
Drug Dosing: Obese Patients01:21

Drug Dosing: Obese Patients

In the United States, obesity is a prominent concern. It is linked to heightened mortality rates due to increased occurrences of conditions such as hypertension, atherosclerosis, coronary artery disease, and diabetes compared to nonobese individuals. A patient is classified as obese if their actual body weight surpasses the ideal or desirable body weight by 20%, based on Metropolitan Life Insurance Company data. Ideal body weights consider average weights and heights for males and females...
Obesity01:24

Obesity

The Body Mass Index (BMI) is a numerical value derived from a person's weight and height, used to categorize individuals into weight ranges. It is calculated using the formula: weight in kilograms divided by height in meters squared. Obesity is a health condition characterized by excessive accumulation of adipose tissue that poses health risks, often diagnosed with a BMI ≥ 30. This excess fat storage occurs when surplus dietary calories are converted into triglycerides and stored in adipocytes...
Mechanism of Cardiac Arrhythmias01:28

Mechanism of Cardiac Arrhythmias

Arrhythmias are irregular heart rhythms occurring when the heart's electrical impulses become abnormal. These disturbances can lead to various symptoms, depending on their severity and the underlying cause. Some common factors contributing to arrhythmias include hypoxia, ischemia, electrolyte imbalances, excessive catecholamine exposure, drug toxicity, and muscle overstretching. Arrhythmias can be classified into two main types based on the rate and site of origin of abnormal heart rhythms.
Hypodermis01:02

Hypodermis

The hypodermis (the subcutaneous layer or superficial fascia) is present directly below the dermis. It connects the skin to the underlying fascia (fibrous tissue) of the bones and muscles. It is not strictly a part of the skin, although the border between the hypodermis and dermis can be difficult to distinguish. The hypodermis consists of well-vascularized, loose, areolar connective tissue and adipose tissue, which functions as a mode of fat storage and provides insulation and cushioning for...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Multi-ancestry gene expression models amplify transcriptome-wide association study discovery and validation.

Nature communications·2026
Same author

Genetically predicted cytotrophoblast gene expression is associated with birth weight and adult body mass index.

Placenta·2026
Same author

Asymmetric nanozymes improve cardiac purine catabolism and alleviate oxidative stress of myocardium to treat ischemic heart disease.

Journal of nanobiotechnology·2026
Same author

Response of an Infant With Presumed Multiple Acyl-CoA Dehydrogenase Deficiency (MADD) to Ketone Supplementation.

American journal of medical genetics. Part A·2026
Same author

Biomimetic Bone Marrow Monocyte Membrane-Fused Extracellular Vesicles for Targeted Therapy of Myocardial Infarction.

Advanced science (Weinheim, Baden-Wurttemberg, Germany)·2026
Same author

Cardiac targeting extracellular vesicles combined with quercetin co-delivery system enhances the therapeutic efficacy of myocardial infarction.

Biomaterials advances·2026

Related Experiment Video

Updated: Jun 24, 2026

Characterization of Adipocyte-Derived Extracellular Vesicle Secretion Using a CD63-GFP Reporter Mouse Model In Vivo and In Vitro
10:40

Characterization of Adipocyte-Derived Extracellular Vesicle Secretion Using a CD63-GFP Reporter Mouse Model In Vivo and In Vitro

Published on: December 5, 2025

Increased Arrhythmic Risk in Obesity Is Transduced by Adipose Tissue-Derived Extracellular Vesicles.

Worawan B Limpitikul1, Marta Garcia-Contreras2, Paul Spangler2

  • 1Cardiology Division, Department of Medicine, Massachusetts General Hospital, Boston, Massachusetts, USA.

JACC. Basic to Translational Science
|June 23, 2026
PubMed
Summary

Obesity promotes heart arrhythmias through direct fat-to-heart communication. Extracellular vesicles from obese fat tissue induce pro-arrhythmic changes in heart cells, revealing a new therapeutic target for obesity-associated arrhythmia.

Keywords:
arrhythmiasatrial fibrillationextracellular vesicleslong QTobesity

Related Experiment Videos

Last Updated: Jun 24, 2026

Characterization of Adipocyte-Derived Extracellular Vesicle Secretion Using a CD63-GFP Reporter Mouse Model In Vivo and In Vitro
10:40

Characterization of Adipocyte-Derived Extracellular Vesicle Secretion Using a CD63-GFP Reporter Mouse Model In Vivo and In Vitro

Published on: December 5, 2025

Area of Science:

  • Cardiology
  • Obesity Medicine
  • Molecular Biology

Background:

  • Obesity is a known risk factor for atrial fibrillation and ventricular arrhythmias.
  • The direct mechanisms by which obesity-associated fat tissue communicates with the heart to promote arrhythmias remain unclear.

Purpose of the Study:

  • To investigate the direct communication between adipose tissue and cardiac myocytes in obesity.
  • To identify the molecular mechanisms and therapeutic targets underlying obesity-associated cardiac arrhythmias.

Main Methods:

  • Utilized induced pluripotent stem cell-derived cardiomyocytes (iPSC-CMs) treated with extracellular vesicles (EVs) from obese visceral adipose tissue (VAT).
  • Employed a transgenic adipose-specific EV-tracking mouse model to study EV trafficking in vivo.
  • Performed transcriptome-wide association studies (TWAS) to link gene expression changes to GWAS data.
  • Investigated the role of the TRPC3 ion channel in mediating pro-arrhythmic effects.

Main Results:

  • Human atrial myocytes from obese individuals and iPSC-CMs treated with VAT EVs exhibited prolonged action potential duration, a pro-arrhythmic phenotype.
  • VAT EVs impaired calcium handling, activated cardiac fibroblasts, and promoted pro-inflammatory macrophage phenotypes.
  • Confirmed preferential trafficking of adipose-derived EVs to the heart in obese mice.
  • Identified causal links between VAT EV-induced gene expression and QT interval/atrial fibrillation in GWAS.
  • Inhibition of TRPC3 normalized action potential duration, suggesting it as a key mediator.

Conclusions:

  • Direct communication via extracellular vesicles from obese adipose tissue contributes to cardiac arrhythmias.
  • VAT EVs promote an arrhythmogenic substrate by altering myocyte electrophysiology, calcium handling, and the cardiac microenvironment.
  • TRPC3 channel activation by VAT EVs represents a novel therapeutic target for obesity-associated arrhythmias.